A miniaturized platform for multiplexed drug response imaging in live tumors.
Tyrosine kinase inhibitors increase MCL1 degradation and in combination with BCLX2/BCL2 inhibitors drive prostate cancer apoptosis.
In vivo detection of drug-induced apoptosis in tumors using Raman Spectroscopy.
Microenvironment-mediated mechanisms of resistance to HER2 inhibitors differ between HER2+ breast cancer subtypes.
MENA confers resistance to paclitaxel in triple-negative breast cancer.
Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine.
Synergistic interactions with PI3K inhibition that induce apoptosis.
Direct evidence for cancer-cell-autonomous extracellular protein catabolism in pancreatic tumors.
Integrated genetic and pharmacologic interrogation of rare cancers.
Tumor cell-driven extracellular matrix remodeling drives haptotaxis during metastatic progression.
First in vivo testing of compounds targeting group 3 medulloblastomas using an implantable microdevice as a new paradigm for drug development.
Parallel in vivo assessment of drug phenotypes at various time points during systemic BRAF inhibition reveals tumor adaptation and altered treatment vulnerabilities.
An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors.